Holen Sie sich die Stockscreener-App
4.13
6.17%
0.24
Handel nachbörslich:
4.13
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MNKD?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.89
Offen:
$4.06
24-Stunden-Volumen:
9.44M
Relative Volume:
1.66
Marktkapitalisierung:
$1.28B
Einnahmen:
$360.78M
Nettoeinkommen (Verlust:
$-23.91M
KGV:
-52.88
EPS:
-0.0781
Netto-Cashflow:
$13.07M
1W Leistung:
+2.48%
1M Leistung:
+7.55%
6M Leistung:
-24.36%
1J Leistung:
+1.23%
1-Tages-Spanne:
$3.98
$4.23
1-Wochen-Bereich:
$3.7101
$4.23
52-Wochen-Spanne:
$2.23
$6.51
Mannkind Corp Stock (MNKD) Company Profile
Firmenname
Mannkind Corp
Sektor
Branche
Telefon
818-661-5000
Adresse
1 CASPER STREET, DANBURY, CA
Compare MNKD vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNKD
Mannkind Corp
|
4.13 | 1.28B | 360.78M | -23.91M | 13.07M | -0.0781 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Mannkind Corp Stock (MNKD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-27 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-13 | Eingeleitet | Leerink Partners | Outperform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-10-10 | Eingeleitet | Leerink Partners | Outperform |
| 2025-07-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-10 | Eingeleitet | Wedbush | Outperform |
| 2024-12-20 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-06-13 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-10-10 | Eingeleitet | Wedbush | Outperform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-24 | Eingeleitet | Oppenheimer | Outperform |
| 2019-10-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-05-14 | Eingeleitet | BTIG Research | Buy |
| 2019-03-04 | Eingeleitet | SVB Leerink | Outperform |
| 2019-02-22 | Eingeleitet | SVB Leerink | Outperform |
| 2018-02-28 | Herabstufung | Maxim Group | Hold → Sell |
| 2017-11-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2017-10-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-10-06 | Bestätigt | Maxim Group | Buy |
| 2017-08-11 | Eingeleitet | Maxim Group | Buy |
| 2016-05-10 | Bestätigt | Piper Jaffray | Underweight |
| 2016-05-10 | Bestätigt | RBC Capital Mkts | Underperform |
| 2016-01-06 | Bestätigt | Piper Jaffray | Underweight |
| 2016-01-06 | Bestätigt | RBC Capital Mkts | Underperform |
| 2015-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Underperform |
| 2015-09-09 | Herabstufung | Piper Jaffray | Neutral → Underweight |
| 2015-08-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-05-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2015-05-11 | Bestätigt | MLV & Co | Hold |
| 2015-04-16 | Bestätigt | RBC Capital Mkts | Outperform |
Alle ansehen
Mannkind Corp Aktie (MNKD) Neueste Nachrichten
MNKD|MannKind Corp|Price:4.130|Chg%:+0.240 - TradingKey
MannKind (MNKD) Stock Looks Undervalued On Cash Flow Yet Mixed On Broader Checks - Yahoo Finance
MannKind Corporation (MNKD) Shares Surge on FDA Approval and $50M Placement - GuruFocus
MannKind Corporation Raises $50 Million in Private Placement Following FDA Approval of Furoscix ReadyFlow - Kalkine Media
MannKind closes $50M financing, wins FDA nod for Furoscix auto-injector - MassDevice
MannKind Corporation (MNKD) stock price, news, quote and history - Yahoo Finance UK
MannKind Announces FDA Approval of Furoscix ReadyFlow, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - FinanzNachrichten.de
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - Benzinga
MNKD Stock Rises 8% On Furoscix ReadyFlow Approval And $50M Funding Boost - Yahoo Finance
MannKind Stock Jumps After FDA Clears Furoscix Auto-Injector, Firm Secures $50 Million PIPE - finance.biggo.com
MannKind Corporation (MNKD) Stock Price, News, Quote & History - Yahoo! Finance Canada
FDA Approves Furosemide Autoinjector for Treatment of Edema in CKD or Heart Failure - Pharmacy Times
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA - Investing.com
MannKind shares surge after FDA approves Furoscix ReadyFlow and company secures $50 million financing - Yahoo Finance
H.C. Wainwright reiterates Buy on MannKind stock ahead of PDUFA By Investing.com - Investing.com Canada
MNKD Stock Rises Premarket As FDA Verdict Nears – Retail Optimism Builds - Stocktwits
Why is MannKind stock rallying today? - Investing.com
MannKind raises $50 million in private placement led by Frazier - Investing.com
MannKind stock jumps 6% on FDA approval, $50M financing - Investing.com
At-home autoinjector delivers IV-equivalent therapy in under 10 seconds - Stock Titan
MannKind (MNKD) Set for Potential Growth Ahead of FDA Decision - GuruFocus
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
Form 4 MannKind Corp For: 21 July By Investing.com - Investing.com South Africa
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
MannKind EVP David Thomson sells $97,641 in MNKD shares on July 17 - Investing.com India
Form 4 MannKind Corp For: 21 July - Investing.com India
MNKD Stock Price, Quote & Chart - ChartMill
MannKind Executive Sells 123,000 Shares Amid Performance Concerns - Intellectia AI
What This MannKind Filing Reveals About Three Years of Underperformance - Yahoo Finance
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Million - Yahoo Finance
Why This MannKind Insider Stock Sale Matters Less Than a 9% Royalty at Risk - Yahoo Finance
Form 4 MannKind Corp For: 20 July By Investing.com - Investing.com Nigeria
MannKind CEO Sells Shares to Cover Tax Liabilities - Intellectia AI
Is MannKind a Stock to Sell After Its CEO Let Go of 363,200 Shares? - Yahoo Finance
MannKind EVP David Thomson sells $97,641 in company stock - Investing.com UK
MannKind director Steven Binder sells $213,089 in company stock By Investing.com - Investing.com India
MannKind EVP David Thomson sells $97,641 in company stock By Investing.com - Investing.com South Africa
Form 4 MannKind Corp For: 17 July By Investing.com - Investing.com South Africa
MannKind Corp (MNKD) EVP receives 70,550 shares from performance RSUs - Stock Titan
MannKind (MNKD) CEO vests 350,260 shares, withholds stock for taxes - Stock Titan
MannKind director Steven Binder sells $213,089 in company stock - Investing.com
MannKind (MNKD) insider schedules 24,109-share sale and reports new RSU, PSU awards - Stock Titan
Planned sale of 52,485 MNKD shares disclosed by MNKD (NASDAQ: MNKD) - Stock Titan
MannKind Corporation (MNKD) Up 20% Since Afrezza FDA Approval - Yahoo Finance
Finanzdaten der Mannkind Corp-Aktie (MNKD)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mannkind Corp-Aktie (MNKD) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Castagna Michael | Chief Executive Officer |
Jul 15 '26 |
Option Exercise |
0.00 |
350,260 |
0 |
2,796,979 |
| Singh Sanjay R | EVP Technical Operations |
Jul 15 '26 |
Option Exercise |
0.00 |
70,550 |
0 |
525,761 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
920,089 |
| Thomson David | EVP Genl Counsel & Secretary |
Jul 17 '26 |
Sale |
4.05 |
24,109 |
97,641 |
797,554 |
| Binder Steven B. | Director |
Jul 15 '26 |
Option Exercise |
0.00 |
93,790 |
0 |
901,798 |
| Binder Steven B. | Director |
Jul 17 '26 |
Sale |
4.06 |
52,485 |
213,089 |
824,918 |
0.46%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):